Drug Trial Radar · NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
185
Planned (sponsor's estimate)
Start
Jun 16, 2026
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- G12D Mutated KRAS
Interventions
VS-7375Drug
Taken by mouth
cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)Drug
Subcutaneous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1Time frame: 6 months
- To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.Time frame: 6 months
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
START- Los Angeles
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
BRCR Global- Coral Springs
Coral Springs, Florida · Recruiting
Mayo Clinical Florida
Jacksonville, Florida · Recruiting
BRCR Global- Tamarac
Tamarac, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Mayo Clinical Rochester
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
NYU-Manhattan
New York, New York · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
START Dallas
Fort Worth, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START- San Antonio
San Antonio, Texas · Recruiting
START- Mountain Region
West Valley City, Utah · Recruiting
UVA Health
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Mason
Seattle, Washington · Recruiting
UW Health
Madison, Wisconsin · Recruiting
ICON Cancer Centre
South Brisbane, Australia · Recruiting
Macquarie University Hospital
Sydney, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
ICON Cancer Centre Townsville
Hyde Park, Queensland, Australia · Recruiting
ICON Kurralta Park
Kurralta Park, South Australia, Australia · Recruiting
ICON Cancer Centre- Hobart
Hobart, Tasmania, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
BRCR Global- San Juan
San Juan, Puerto Rico · Recruiting
BRCR- Yauco
Yauco, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.